Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.80 |
| ▸ | ARG2 | P78540 | 4/20 | 0.50 |
| ▸ | ARG1 | P05089 | 3/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL2589784 | 1.00 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL31679370 | 1.00 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL20952564 | 1.00 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL28257457 | 1.00 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL18528930 | 1.00 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL13935114 | 1.00 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL1425215 | 1.00 | GSR (0.80) | GSRARG2ARG1RNPEPCYP1A2 | |
| Lysine SCHEMBL614905 | 0.96 | GSR (0.74) | GSRARG2ARG1RNPEPCYP1A2 | |
| Aspartic Acid SCHEMBL8508697 | 0.94 | GSR (0.71) | GSRARG2ARG1RNPEPCYP1A2 | |
| Aspartic Acid SCHEMBL8508699 | 0.94 | GSR (0.71) | GSRARG2ARG1RNPEPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119732401-A | Antioxidant and application thereof in meat products | 湖北省兴发磷化工研究院有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-117487676-A | Concentrated microecological preparation for pig farm on-site fermentation and preparation method thereof | 福建益昕葆生物制药有限公司 | 2024-02-02 | — | — | CN | claimed |
| EP-4233892-A2 | STABLE ANTI-IFNAR1 FORMULATION | Astrazeneca AB (SE) | 2023-08-30 | — | — | EP | claimed |
| CN-116375237-A | Recycling method of salt-containing wastewater produced by crude heparin sodium | 中盐金坛盐化有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| EP-3769781-B1 | STABLE ANTI-IFNAR1 FORMULATION | ASTRAZENECA AB (SE) | 2023-04-19 | — | — | EP | claimed |
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | AMGEN INC. | 2023-03-16 | — | — | US | claimed |
| EP-4103235-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | Amgen Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| CN-115279404-A | Formulation of human anti-TSLP antibodies and methods of treating inflammatory diseases | 安进公司 | 2022-11-01 | — | — | CN | claimed |
| US-20220218607-A1 | STABLE, LOW-VISCOSITY ANTIBODY FORMULATIONS AND USES THEREOF | SANOFI SA (FR) | 2022-07-14 | — | — | US | claimed |
| CN-110169930-B | Aqueous polyurethane-coated sunscreen aqueous dispersion and preparation method and application thereof | 万华化学（宁波）有限公司 | 2022-07-12 | — | — | CN | claimed |
| US-10233225-B2 | Single chain insulin agonists exhibiting high activity at the insulin receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-19 | — | — | US | claimed |
| EP-3337502-A1 | STABLE ANTI-IFNAR1 FORMULATION | Astrazeneca AB (SE) | 2018-06-27 | — | — | EP | claimed |
| WO-2017031288-A1 | STABLE ANTI-IFNAR1 FORMULATION | MEDIMMUNE, LLC (US) | 2017-02-23 | — | — | WO | claimed |
| US-9353357-B2 | Polypeptides having phytase activity and the encoding nucleic acids | AB ENZYMES GMBH (DE) | 2016-05-31 | — | — | US | claimed |
| US-20140242249-A1 | POLYPEPTIDE HAVING PHYTASE ACTIVITY AND INCREASED TEMPERATURE RESISTANCE OF THE ENZYME ACTIVITY, AND NUCLEOTIDE SEQUENCE CODING SAID POLYPEPTIDE | AB ENZYMES GMBH (DE) | 2014-08-28 | — | — | US | claimed |
| EP-2428565-B1 | Polypeptide having phytase activity and increased temperature resistance of the enzyme activity, and nucleotide sequence coding said polypeptide | AB ENZYMES GMBH (DE) | 2013-09-25 | — | — | EP | claimed |
| US-20110262619-A1 | POLYPEPTIDE HAVING PHYTASE ACTIVITY AND INCREASED TEMPERATURE RESISTANCE OF THE ENZYME ACTIVITY, AND NUCLEOTIDE SEQUENCE CODING SAID POLYPEPTIDE | AB ENZYMES GMBH (DE) | 2011-10-27 | — | — | US | claimed |
| EP-1044672-B1 | Water-in-oil emulsified cosmetic | SHISEIDO CO LTD (JP) | 2007-03-07 | — | — | EP | claimed |
| US-4534881-A | Inhibition of inorganic or biological CaCO3 deposition by poly amino acid derivatives | UNIVERSITY OF SOUTH ALABAMA (US) | 1985-08-13 | — | — | US | claimed |
| US-4464397-A | TREATMENT OF MUSCLE FATIGUE | WICO DISTRIBUTION CORP., A DE CORP. | 1984-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | TSLP, IL5, ORAI1 | GSR 4256/4885ARG2 2715/4885ARG1 650/4885 |
| US-10233225-B2 | Single chain insulin agonists exhibiting high activity at the insulin receptor | IGF1R, GPR119, IRS1 | GSR 4183/4885ARG2 2069/4885ARG1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.